Sacituzumab Tirumotecan Extends Survival in Endometrial Cancer
A phase III trial showed the drug improved both progression-free and overall survival over physician's choice chemotherapy.
Updated on Nov. 10, 2026 in Cancer
In the TroFuse-005 phase III trial, sacituzumab tirumotecan met both primary endpoints, progression-free survival and overall survival, versus physician's choice of doxorubicin or weekly paclitaxel in advanced or recurrent endometrial cancer. The trial enrolled patients previously exposed to platinum chemotherapy and an immune checkpoint inhibitor.
Why it matters
Patients with advanced endometrial cancer who have already progressed on platinum chemotherapy and immunotherapy have limited options, so a regimen that delays progression and extends survival addresses a clear clinical need. The results were presented at the annual European Society for Medical Oncology congress and are part of a broader push to develop antibody-drug conjugates for solid tumors.
The phase III TroFuse-005 trial showed a median progression-free survival of 7.2 months with sacituzumab tirumotecan versus 3.9 months with comparator, and a median overall survival of 19 months versus 12 months, with a hazard ratio of 0.68 for death. The extraction does not report adverse event rates or longer-term quality-of-life outcomes.
The players
Domenica Lorusso
Lorusso is an Italian oncologist and investigator on the TroFuse-005 trial who is based in Italy.
European Society for Medical Oncology
The European Society for Medical Oncology is a professional association of cancer specialists that hosts an annual congress where major clinical oncology trials are presented.
The details
The trial compared sacituzumab tirumotecan against physician's choice of doxorubicin or weekly paclitaxel, and progression was assessed by blinded independent central review. Sacituzumab tirumotecan reduced the risk of progression by 41% and the risk of death by 32%, and the overall response rate was 35% versus 17% for comparator.
Timeline
The TroFuse-005 results were presented at the annual European Society for Medical Oncology congress.
Coverage of the TroFuse-005 results was published on November 10, 2026.
Health Landscape
The TroFuse-005 results add phase III survival evidence to sacituzumab tirumotecan's regulatory file while the FDA is reviewing the drug for a post-platinum and post-immunotherapy indication. The trial's authors have suggested the drug should become the new standard of care and the control arm for future endometrial cancer trials.
For patients with advanced endometrial cancer who have already received platinum chemotherapy and an immune checkpoint inhibitor, the trial suggests a treatment option that may delay progression and extend survival. Whether this drug becomes available depends on the pending FDA review, and the extraction does not describe side effects or how it would be administered.
The takeaway
Sacituzumab tirumotecan improved both progression-free and overall survival in previously treated endometrial cancer, and the trial's authors have suggested it may become the new standard of care. Readers should watch for the FDA's decision and for safety data that will show how the benefits weigh against side effects.
Further reading
For more on treatment advances across tumor types, see the Cancer section.
